Bayer/Immune Response to co-develop gene therapy for hemophilia A.
BAYER/IMMUNE RESPONSE HEMOPHILIA A GENE THERAPY COLLABORATION is worth $10 mil. in up-front funding to Immune Response and could be worth up to $100 mil. in development and commercialization costs, the Carlsbad, Calif.-based company estimated. Under a co-development agreement announced July 9, Immune Response will receive a $6 mil. license fee, a $4 mil. equity investment, research funding for the hemophilia A program, milestone payments and royalties on future product sales.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth